Biostatistician

The $115,000 median posted on BLS-style sites hides large structural differences:

Entry-level (Master's, 0-3 years): $90,000-$115,000 US base, £45,000-£60,000 UK base. Pharma and biotech sit at the top; academic medical centers pay 20-25% below; CROs (IQVIA, Parexel, ICON, Labcorp) pay in the middle.

Senior (5-8 years): $135,000-$185,000 US, £70,000-£95,000 UK. Big Pharma (Pfizer, Roche/Genentech, Merck, GSK) and the major CROs sit at the top. Add equity at biotech start-ups, which can substantially exceed cash.

Principal / Lead Biostatistician: $190,000-$280,000 US, £100,000-£140,000 UK. At this level, FDA/EMA submission experience and adaptive trial expertise matter more than years of service.

Fully remote roles are now mainstream in this field — most major employers hire across the US (and across the UK), so you're not geographically capped to high-pay metros.

Bonuses run 10-20% of base in industry; academia pays zero bonus but offers tenure, intellectual freedom, and a different total return.

Pharma or biotech direct after the Master's or PhD. Fastest path to high salary. Standard route: MS in Biostatistics, Statistics, or a Quantitative Public Health track. Entry openings are rarely listed publicly — most come via specialist recruiters (e.g., RBW Consulting, PharmiWeb, ProClinical in UK). Internship during the Master's almost always converts.

CRO as launchpad. CROs systematically hire and train junior biostatisticians. 2-3 years there is the fastest ticket to senior pharma roles. Travel and pressure higher than in-house pharma, but the learning curve is steep and the resume opens doors.

Academic route via PhD. PhD at a major medical center (Harvard, Hopkins, UNC, Oxford, Cambridge, UCL) opens both academic tracks (R1 faculty) and industry exits. Industry switchers bring methodological prestige; staying academic costs 6-10 years for uncertain tenure-track outcomes.

Adaptive Trials. Designs that modify parameters based on interim results. FDA and EMA have steadily accepted more adaptive designs over the past four years. Solid methodological skill (Bayesian methods, sample size re-estimation, group sequential designs) commands a 15-20% premium over conventional clinical biostatistics.

Real-World Evidence (RWE). Analyzing claims, EHR, and registry data instead of (or alongside) RCTs. FDA's RWE framework and EMA's increasing acceptance for label expansions and reimbursement submissions has created a critical shortage. The profile is rare because it combines epidemiology + statistics + data engineering.

Bayesian methods at scale. Most classical biostatisticians can't write Stan or PyMC. Pair R + Stan and you become the rare profile that adaptive trials and RWE both need.

SAS remains mandatory. Despite all the R hype, FDA submissions are still overwhelmingly SAS-based. If you can't code production-quality SAS, you're locked out of the highest-paying industry roles. Not all of them — but the top tier.

30-40% analysis and programming in R or SAS — actual coding, tables, figures, listings.

25-30% writing and reviewing Statistical Analysis Plans (SAPs), aligning with clinical, medical, and regulatory teams.

15-20% cross-functional meetings, especially clinical operations, medical writing, and regulatory affairs touchpoints.

10-15% documentation: CSR contributions, submission deliverables, responses to FDA/EMA questions.

5-10% methodological work — internal working groups, conference prep, ongoing literature reading.

Remote work is the norm in pharma since 2022, with 1-2 office days per week for cross-functional teams and fully remote roles common at senior levels.

Methodological depth vs tool fluency. Many candidates show R portfolios and bootcamp certs but stumble on power calculations, multiple comparisons, or survival analysis fundamentals in interviews. Industry tests this on purpose. If 'Bonferroni-Holm' makes you hesitate, you fail.

GCP and ICH compliance. PhD-out-of-academia hires often don't know GCP (Good Clinical Practice) and ICH guidelines. Industry expects familiarity from day one. A 1-day training (~$300-$600) is a smart pre-investment for academic-to-industry switchers.

CRO tier matters more than you'd think. Top-tier (IQVIA, Parexel, ICON, Labcorp) provides structured training and brand prestige. Mid-tier often promises faster responsibility but rarely delivers. Before signing, talk to current employees on LinkedIn — answers vary widely.

The contractor route. Senior biostatisticians can move to independent consulting at day rates of $1,500-$3,000 (US) or £900-£1,800 (UK). Requires 7+ years in industry plus a network. The take-home math beats W-2 senior roles after the second year — but lose the bonus, equity, and pension structure.

If you have a Master's or PhD in stats and want to break in: go to the [ASA Statistical Practice section](https://www.amstat.org) (US) or the [Royal Statistical Society Careers](https://rss.org.uk) (UK). Both list industry and academic posts that don't all appear on LinkedIn.

If you're switching from an adjacent field (Data Science, classical statistics, bioinformatics): search LinkedIn for 'Statistical Programmer' or 'Junior Biostatistician' — both are bridge roles that accept R/SAS basics without requiring a biostatistics-specific degree.

If you're already in industry and want to level up: look at the next JSM (Joint Statistical Meetings) program or the PSI Conference in the UK. Presenting a poster on adaptive designs or RWE often leads to direct outreach from senior recruiters afterward — the market is small enough that senior hiring happens through networks, not job boards.